Zenotech Laboratories Ltd

Zenotech Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 13 June 2026. This revision reflects deteriorating financial performance, expensive valuation metrics, and a shift towards bearish technical indicators, signalling heightened risks for investors.

Zenotech Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 8 June 2026, driven primarily by a shift in technical indicators despite ongoing financial headwinds. The micro-cap pharmaceutical company’s Mojo Score improved to 34.0, reflecting a nuanced balance between technical recovery and persistent valuation and profitability concerns.

Zenotech Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 1 June 2026. This revision reflects deteriorating financial performance, expensive valuation metrics, and increasingly bearish technical indicators, signalling heightened risks for investors amid ongoing underperformance relative to benchmark indices.

Zenotech Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in technical indicators despite ongoing financial challenges. The company’s micro-cap status, combined with a complex interplay of valuation, quality, financial trends, and technical signals, has led to this recalibration of its market outlook as of 25 May 2026.

Zenotech Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its quality, valuation, financial trends, and technical indicators. The downgrade reflects deteriorating fundamentals, weak quarterly results, and increasingly bearish technical signals, signalling caution for investors in this micro-cap pharmaceutical stock.

Zenotech Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators despite ongoing financial challenges. This nuanced change reflects a mildly improved technical outlook amid persistent valuation and profitability concerns, offering investors a complex picture of the micro-cap pharmaceutical player’s current standing.

Zenotech Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating following a marked deterioration in its financial performance, valuation metrics, and technical indicators. The pharmaceutical company’s quarterly results for March 2026 reveal significant declines in profitability and sales, while technical trends have shifted to bearish, signalling increased caution for investors.

Zenotech Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a significant downturn in its financial performance for the quarter ended March 2026. The company’s key metrics, including net sales, profit after tax, and operating margins, have all deteriorated sharply compared to its recent historical averages, signalling a shift from positive to negative financial trends.

Zenotech Laboratories Ltd., a micro-cap pharmaceutical company specialising in generic injectables for oncology and anaesthesiology, reported a concerning quarter ending March 2026, with net profit plunging into negative territory at ₹-3.15 crores—a dramatic reversal from ₹1.93 crores in Q3 FY26. The company, with a market capitalisation of ₹281.00 crores, saw its stock trading at ₹45.53 as of April 29, 2026, reflecting a marginal 0.22% gain in the session following the results announcement, though the broader picture reveals significant underlying operational challenges.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 04 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

While the broader market showed signs of recovery, Zenotech Laboratories Ltd has continued its downward trajectory, hitting a fresh 52-week low of Rs 33.55 on 30 Mar 2026. This decline comes amid a backdrop of underperformance relative to both its sector and benchmark indices.

For the third consecutive session, Zenotech Laboratories Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 34.5 on 27 Mar 2026. This marks a significant 52.7% drop from its peak of Rs 72.87 within the last year, underscoring persistent selling pressure despite some recent operational improvements.

Zenotech Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Zenotech Laboratories Ltd’s share price declined sharply to a fresh 52-week low of Rs.34.99 on 23 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low comes amid a broader market weakness and persistent underperformance relative to its sector and benchmark indices.